The Global Hypertension Drugs Market accounted for US$24,351 Mn in 2020 and is expected to reach US$31,502 Mn with a considerable CAGR of 3.4% during the forecast period of 2021 to 2028.
According to the World Health Organization (WHO), hypertension is one of the silent killers of the twenty-first century and one of the most serious global public health issues. The global burden of hypertension has risen over time, mainly because of population expansion, lifestyle changes, and aging. Cardiovascular problems, stroke, heart disease, kidney failure, blindness, premature mortality, and disability are all linked to hypertension. Hypertension is curable and treatable, but it requires participation from individuals, government and commercial sectors, health personnel, civil society, and individual awareness.
Market Growth Drivers:
|Market||Hypertension Drugs Market|
|Market Size 2020||US$24,351 Mn|
|Market Forecast 2028||US $31,502 Mn|
|CAGR||3.4% During 2021 - 2028|
|Analysis Period||2017 - 2028|
|Forecast Data||2021 - 2028|
|Segments Covered||By Product Type, By Condition, By Medication Type, By Distribution Channeland By Geography
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||
Takeda Pharmaceutical Co., Novartis AG, Abbott, Sanofi, Bayer AG, Johnson and Johnson Services Inc., Gilead, Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline Plc.,Astrazeneca,and F. Hoffmann La-Roche Ltd.among others.
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
10 hrs of free customization and expert consultation
Covid-19 Impact on the Global Hypertension Drugs Industry
Hypertension is the leading cause of disability-adjusted life years lost worldwide. The majority of people over the age of 60 have hypertension, and it's been hypothesized that they are more vulnerable to COVID-19's effects. For instance, British Heart Foundation and the Health Service Executives (Ireland) states that there may be an increased risk in hypertension patients from the effects of COVID-19. However, early modest case studies found no evidence of an increase in hypertension in COVID-19 patients admitted to the hospital. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team reported a major case series from China, with a case fatality rate of 2.3 percent (1023 of 44,672 confirmed cases), rising to 6.0 percent in people with hypertension. Thus, the patients with high blood pressure are having a certain risk of life in the covid-19 times. This element has raised consumer awareness, which has increased global hypertension medicine sales.
The key factor driving the global hypertension medications market is the rising incidence of hypertension around the world. For instance, hypertension was a primary or contributing cause of over half a million fatalities in the United States in 2019. Nearly half of Americans (47 percent, or 116 million) have hypertension. Rising initiatives by private and public organizations have also aided the worldwide hypertension medications market share. For example, to reduce the prevalence by 25% by 2025, WHO along with United States Center for Disease Control and Prevention launched the Global Heart Initiative in 2016. Likewise, in India, the government's hypertension screening program in 2019 - India Hypertension Control Initiative (IHCI), which is currently being implemented in 25 districts across the country, would now be expanded to 100 districts across all states. The Indian Council of Medical Research (ICMR), in partnership with the World Health Organization (WHO) and the Ministry of Health and Family Welfare, will expand the initiative. Over the next four years, the project will speed the adoption of high-quality hypertension therapy for over 15 crore people, preventing fatalities from heart attacks, strokes, and kidney failure.
Additionally, the growing prevalence of chronic disorders across the world is another factor propelling the global hypertension drug industry's growth. According to the 2018 National Health Interview Survey (NHIS), 51.8 percent of U.S. people had at least one of ten chronic diseases diagnosed (diabetes, arthritis, stroke, hypertension, cancer, chronic obstructive pulmonary disease, current asthma, coronary heart disease, hepatitis, and weak or failing kidneys). Despite the rising demand for hypertension drugs, certain limitations are restricting the market growth, such as side effects from hypertension medications, and the high cost of the treatment. Common side effects from hypertension medications are constipation, erection problems, diarrhea, dry mouth, etc. Furthermore, increasing R&D activity in the healthcare sector to discover novel medicines is predicted to generate several growth prospects between 2021 and 2028.
The global Hypertension Drugs market is segmented based on product type, condition, medication type, distribution channel, and region.
Market by Product Type
Among product types, the Angiotensin II Receptor Blockers (ARBs) segment obtained a significant amount of share in 2020. Angiotensin II is an enzyme that causes blood vessels to constrict. ARBs (angiotensin II receptor blockers) preventthe enzyme from reaching certain receptors, allowing blood arteries to remain open. Thus, they are prescribed to patients suffering from hypertension. Moreover, calcium channel blockers also gained a significant percentage of market share due to the fact that they have fewer adverse effects than other types of products.
Market by Condition
In 2020, primary hypertension segment accounted for the highest share of the global market. This is because primary hypertension, also known as essential hypertension, accounts for more than 90% of all hypertension cases. Although there is no one cause for primary hypertension, several risk factors such as smoking, family history, a sedentary lifestyle, and being overweight or obesity increases individual's chances of having the illness.
Market by Medication Type
Based on medication type, monotherapy accounted for a significant market share in 2020 and is likely to continue its trend throughout the forecast period 2021 – 2028. However, combination therapy is expected to attain a stable growth rate throughout the review period. In order to reach therapeutic goals, the focus on combination therapy in the antihypertensive medicines industry is projected to grow. In the current market scenario, established and emerging businesses are increasingly focusing on the development of successful combination medicines.
Market by Distribution Channel
In 2020, the hospital pharmacies generated a substantial amount of share in the global hypertension drug market. On the other hand, the online pharmacies are anticipated to register the fastest growth rate during the forecast timeframe due to the growing e-commerce portals that offer attractive discounts, free home delivery, as well as cash on delivery options.
Hypertension Drugs Market Regional Overview
Middle East & Africa
North America acquired the largest shares in the global hypertension drugs market
In 2020, North America witnessed a significant amount of hypertension patients with a majority coming from the United States. For instance, according to the American Heart Association (AHA), hypertension affects approximately 86 million adults (34 percent) in the United States. In addition, the growing geriatric population in the region is also an important aspect of the escalated demand for the hypertension drugs industry. The Rural Health Information Hub data suggest that in the United States, currently there are more than 46 million older individuals aged 65 and up, and that number is predicted to rise to nearly 90 million by 2050.
Meanwhile, the Asia-Pacific region is likely to attain the fastest CAGR during the forecast years. The region's rapid expansion is related to an increase in the incidence of chronic diseases, sedentary lifestyles, population growth, and an increase in pollution levels. Furthermore, rising government schemes and efforts, rising investments in the healthcare sector, and rising awareness among the region's people are all contributing to the market's growth.
This section of the research identifies a number of significant market players. Some of the prominent vendors offered in the report include Takeda Pharmaceutical Co., Novartis AG, Abbott, Sanofi, Bayer AG, Johnson and Johnson Services Inc., Gilead, Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline Plc.,Astrazeneca,and F. Hoffmann La-Roche Ltd.among others.
The estimated value of global Hypertension Drugs Market in 2020 was accounted to be US$24,351 Mn
The projected CAGR of Hypertension Drugs market during the analysis period of 2021 to 2028 is 3.4%
The prominent players of the global Hypertension Drugs Market involve Takeda Pharmaceutical Co., Novartis AG, Abbott, Sanofi, Bayer AG, Johnson and Johnson Services Inc., Gilead, Pfizer Inc., GlaxoSmithKline Plc.,Merck & Co. Inc., Astrazeneca,F. Hoffmann La-Roche Ltd. and others
North America held the dominating share for Hypertension Drugs during the analysis period of 2021 to 2028
Asia-Pacific region exhibited fastest growing CAGR for Hypertension Drugs during the analysis period of 2021 to 2028
Growing incidences of hypertension, rising initiatives by public and private organizations, and growth in R&D leading to new therapies are the prominent factors that fuel the growth of global Hypertension Drugs Market
Based on condition, primary hypertension segment held the maximum share for Hypertension Drugs Market in 2020